Works about BORTEZOMIB

Results: 1600

Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.

Published in:

JAMA Network Open, 2025, v. 8, n. 6, p. e2516296, doi. 10.1001/jamanetworkopen.2025.16296

By:

Marrero, Richard J.;
Shastri, Vivek M.;
Nicolet, Deedra;
Mrózek, Krzysztof;
Walker, Christopher J.;
Blum, William G.;
Powell, Bayard L.;
Kolitz, Jonathan E.;
Moore, Joseph O.;
Uy, Geoffrey L.;
Stock, Wendy;
Carroll, Andrew J.;
Byrd, John C.;
Aplenc, Richard;
Cooper, Todd M.;
Gamis, Alan S.;
Wu, Huiyun;
Pounds, Stanley;
Wang, Yi-Cheng;
Alonzo, Todd A.

Publication type:

Article

Mussel-Inspired Electrospun Smart Magnetic Nanofibers for Hyperthermic Chemotherapy.

Published in:

Advanced Functional Materials, 2015, v. 25, n. 19, p. 2867, doi. 10.1002/adfm.201500389

By:

GhavamiNejad, Amin;
Sasikala, Arathyram Ramachandra Kurup;
Unnithan, Afeesh Rajan;
Thomas, Reju George;
Jeong, Yong Yeon;
Vatankhah‐Varnoosfaderani, Mohammad;
Stadler, Florian J.;
Park, Chan Hee;
Kim, Cheol Sang

Publication type:

Article

Correction to: G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis.

Published in:

2019

By:

Bittencourt, L. F. F.;
Negreiros-Lima, G. L.;
Sousa, L. P.;
Silva, A. G.;
Souza, I. B. S.;
Ribeiro, R. I. M. A.;
Dutra, M. F.;
Silva, R. F.;
Dias, A. C. F.;
Soriani, F. M.;
Martins, W. K.;
Barcelos, L. S.

Publication type:

Correction Notice

G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis.

Published in:

Journal of Neuro-Oncology, 2019, v. 144, n. 3, p. 463, doi. 10.1007/s11060-019-03252-6

By:

Bittencourt, L. F. F.;
Negreiros-Lima, G. L.;
Sousa, L. P.;
Silva, A. G.;
Souza, I. B. S.;
Ribeiro, R. I. M. A.;
Dutra, M. F.;
Silva, R. F.;
Dias, A. C. F.;
Soriani, F. M.;
Martins, W. K.;
Barcelos, L. S.

Publication type:

Article

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.

Published in:

Journal of Neuro-Oncology, 2016, v. 130, n. 1, p. 193, doi. 10.1007/s11060-016-2234-6

By:

McCracken, D.;
Celano, Emma;
Voloschin, Alfredo;
Read, William;
Olson, Jeffrey

Publication type:

Article

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.

Published in:

Journal of Neuro-Oncology, 2016, v. 129, n. 1, p. 139, doi. 10.1007/s11060-016-2156-3

By:

Raizer, Jeffrey;
Chandler, James;
Ferrarese, Roberto;
Grimm, Sean;
Levy, Robert;
Muro, Kenji;
Rosenow, Joshua;
Helenowski, Irene;
Rademaker, Alfred;
Paton, Martin;
Bredel, Markus

Publication type:

Article

A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.

Published in:

Journal of Neuro-Oncology, 2015, v. 125, n. 1, p. 191, doi. 10.1007/s11060-015-1894-y

By:

Odia, Yazmín;
Kreisl, Teri;
Aregawi, Dawit;
Innis, Ellen;
Fine, Howard

Publication type:

Article

Proteasome inhibition induces macrophage apoptosis via mitochondrial dysfunction.

Published in:

Journal of Biochemical & Molecular Toxicology, 2021, v. 35, n. 11, p. 1, doi. 10.1002/jbt.22894

By:

Jieyan Wang;
Yingling Wang;
Shihan He;
Zhu Wang;
Qiong Deng;
Hui Liang

Publication type:

Article

Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases.

Published in:

Clinical Rheumatology, 2023, v. 42, n. 7, p. 1965, doi. 10.1007/s10067-023-06559-y

By:

Modica, Renee F.;
Thatayatikom, Akaluck;
Bell-Brunson, Denise H.;
Elder, Melissa E.

Publication type:

Article

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.

Published in:

2017

By:

Latifoltojar, Arash;
Hall-Craggs, Margaret;
Bainbridge, Alan;
Rabin, Neil;
Popat, Rakesh;
Rismani, Ali;
D'Sa, Shirley;
Dikaios, Nikolaos;
Sokolska, Magdalena;
Antonelli, Michela;
Ourselin, Sebastien;
Yong, Kwee;
Taylor, Stuart;
Halligan, Steve;
Punwani, Shonit;
Taylor, Stuart A

Publication type:

journal article

Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.

Published in:

Oncology, 2023, v. 101, n. 5, p. 343, doi. 10.1159/000529341

By:

Fujiwara, Masaki;
Uchida, Mayako;
Endo, Mirai;
Goto, Makoto;
Shimizu, Tadashi

Publication type:

Article

Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database.

Published in:

Oncology, 2022, v. 100, n. 3, p. 188, doi. 10.1159/000521448

By:

Satoki, Aya;
Uchida, Mayako;
Fujiwara, Masaki;
Uesawa, Yoshihiro;
Shimizu, Tadashi

Publication type:

Article

Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02036-x

By:

Wang, Ya;
Dai, ZiYu;
Xiao, Shengying;
Zeng, Furen;
Lu, YiChen

Publication type:

Article

Comparison of the apoptotic effects of bortezomib using 2D and 3D co-culture models of THP-1 derived macrophage and A549 lung cancer.

Published in:

Journal of Research in Pharmacy, 2021, v. 25, n. 4, p. 490, doi. 10.29228/jrp.39

By:

ENGÜR ÖZTÜRK, Selin;
KAYA TİLKİ, Elif;
DİKMEN, Miriş;
CANTÜRK, Zerrin

Publication type:

Article

Bortezomib synergizes with nocodazole in p53 mediated DNA damage response signalling in A549 lung cancer cells.

Published in:

Journal of Research in Pharmacy, 2021, v. 25, n. 3, p. 287, doi. 10.29228/jrp.19

By:

ALBAYRAK, Gülşah

Publication type:

Article

Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.

Published in:

Modern Rheumatology, 2018, v. 28, n. 6, p. 986, doi. 10.1080/14397595.2018.1432331

By:

Tomonori Ishii;
Yoshiya Tanaka;
Atsushi Kawakami;
Kazuyoshi Saito;
Kunihiro Ichinose;
Hiroshi Fujii;
Yuko Shirota;
Tsuyoshi Shirai;
Yoko Fujita;
Ryu Watanabe;
Shih-Wei Chiu;
Takuhiro Yamaguchi;
Hideo Harigae

Publication type:

Article

Bortezomib treatment prevents glomerulosclerosis associated with lupus nephritis in a murine model through suppressive effects on the immune and renin-angiotensin systems.

Published in:

Modern Rheumatology, 2017, v. 27, n. 1, p. 77, doi. 10.3109/14397595.2016.1170957

By:

Yuko Matsuki-Muramoto;
Kazuhisa Nozawa;
Kaori Uomori;
Iwao Sekigawa;
Yoshinari Takasaki

Publication type:

Article

Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-01992-7

By:

Prabhu, Kirti S.;
Ahmad, Fareed;
Kuttikrishnan, Shilpa;
Leo, Rari;
Ali, Tayyiba Akbar;
Izadi, Mahmoud;
Mateo, Jericha M.;
Alam, Majid;
Ahmad, Aamir;
Al-Shabeeb Akil, Ammira S.;
Bhat, Ajaz A.;
Buddenkotte, Joerg;
Pourkarimi, Ehsan;
Steinhoff, Martin;
Uddin, Shahab

Publication type:

Article

The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 6, p. 2384, doi. 10.3390/jcm12062384

By:

Popek-Marciniec, Sylwia;
Styk, Wojciech;
Wojcierowska-Litwin, Magdalena;
Szudy-Szczyrek, Aneta;
Dudek, Paul;
Swiderska-Kolacz, Grazyna;
Czerwik-Marcinkowska, Joanna;
Zmorzynski, Szymon

Publication type:

Article

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 112, doi. 10.3390/jcm11010112

By:

Mikulski, Damian;
Robak, Paweł;
Perdas, Ewelina;
Węgłowska, Edyta;
Łosiewicz, Aleksandra;
Dróżdż, Izabela;
Jarych, Dariusz;
Misiewicz, Małgorzata;
Szemraj, Janusz;
Fendler, Wojciech;
Robak, Tadeusz

Publication type:

Article

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 2, p. 552, doi. 10.3390/jcm9020552

By:

Di Lernia, Giuseppe;
Leone, Patrizia;
Solimando, Antonio Giovanni;
Buonavoglia, Alessio;
Saltarella, Ilaria;
Ria, Roberto;
Ditonno, Paolo;
Silvestris, Nicola;
Crudele, Lucilla;
Vacca, Angelo;
Racanelli, Vito

Publication type:

Article

The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation—A Single-Center Case Series.

Published in:

Journal of Clinical Medicine, 2020, v. 9, n. 2, p. 529, doi. 10.3390/jcm9020529

By:

Kolonko, Aureliusz;
Słabiak-Błaż, Natalia;
Karkoszka, Henryk;
Więcek, Andrzej;
Piecha, Grzegorz

Publication type:

Article

Left kidney undifferentiated spindle cell sarcoma with myeloid cell leukemia-1 amplification: Therapeutic response to bortezomib, venetoclax, and dexamethasone therapy.

Published in:

Journal of Cancer Research & Practice, 2023, v. 10, n. 4, p. 154, doi. 10.4103/ejcrp.eJCRP-D-23-00026

By:

Tang, Cheng-Yu;
Yen, Chueh-Chuan

Publication type:

Article

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.

Published in:

Oncologist, 2024, v. 29, n. 11, p. e1552, doi. 10.1093/oncolo/oyae244

By:

Li, Jian-Rong;
Parthasarathy, Abinand Krishna;
Kannappan, Aravind Singaram;
Arsang-Jang, Shahram;
Dong, Jing;
Cheng, Chao

Publication type:

Article

EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.

Published in:

Oncologist, 2020, v. 25, n. 12, p. 1067, doi. 10.1002/onco.13554

By:

Michaleas, Sotirios;
Penninga, Elisabeth;
Hovgaard, Doris;
Dalseg, Anne‐Marie;
Rosso, Aldana;
Sarac, Sinan B.;
Jimenez, Jorge Camarero;
Fernández, Lucia López‐Anglada;
Fernández, Carolina Prieto;
Mangas‐SanJuan, Victor;
Garcia, Isabel;
Payares‐Herrera, Concepcion;
Sancho‐López, Aranzazu;
Enzmann, Harald;
Castro Lopes Silva, Marcia Sofia Sanches;
Duarte, Sílvia;
Pignatti, Francesco

Publication type:

Article

1q21 Gain Combined with High‐Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.

Published in:

Oncologist, 2019, v. 24, n. 11, p. e1132, doi. 10.1634/theoncologist.2019-0132

By:

Li, Xiaozhe;
Chen, Wenming;
Wu, Yin;
Li, Jianyong;
Chen, Lijuan;
Fang, Baijun;
Feng, Ying;
Liu, Junru;
Chen, Meilan;
Gu, Jingli;
Huang, Beihui;
Li, Juan

Publication type:

Article

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.

Published in:

Oncologist, 2019, v. 24, n. 1, p. 16, doi. 10.1634/theoncologist.2018-0452

By:

Del Rivero, Jaydira;
Edgerly, Maureen;
Ward, Jean;
Madan, Ravi A.;
Balasubramaniam, Sanjeeve;
Fojo, Tito;
Gramza, Ann W.

Publication type:

Article

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.

Published in:

Oncologist, 2018, v. 23, n. 5, p. 594, doi. 10.1634/theoncologist.2017-0328

By:

Tzogani, Kyriaki;
Penninga, Elisabeth;
Schougaard Christiansen, Marie Louise;
Hovgaard, Doris;
Sarac, Sinan B.;
Camarero Jimenez, Jorge;
Garcia, Isabel;
Lafuente, Marta;
Sancho‐López, Arantxa;
Salmonson, Tomas;
Gisselbrecht, Christian;
Pignatti, Francesco

Publication type:

Article

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

Published in:

Oncologist, 2018, v. 23, n. 5, p. 631, doi. 10.1634/theoncologist.2017-0301

By:

Tzogani, Kyriaki;
van Hennik, Paula;
Walsh, Ita;
De Graeff, Pieter;
Folin, Annika;
Sjöberg, Jan;
Salmonson, Tomas;
Bergh, Jonas;
Laane, Edward;
Ludwig, Heinz;
Gisselbrecht, Christian;
Pignatti, Francesco

Publication type:

Article

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.

Published in:

Oncologist, 2017, v. 22, n. 11, p. 1347, doi. 10.1634/theoncologist.2017-0229

By:

Bhatnagar, Vishal;
Gormley, Nicole J.;
Luo, Lola;
Shen, Yuan Li;
Sridhara, Rajeshwari;
Subramaniam, Sriram;
Shen, Guoxiang;
Ma, Lian;
Shord, Stacy;
Goldberg, Kirsten B.;
Farrell, Ann T.;
McKee, Amy E.;
Pazdur, Richard

Publication type:

Article

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma.

Published in:

Oncologist, 2017, v. 22, n. 5, p. 549, doi. 10.1634/theoncologist.2016-0328

By:

Lee, Hun Ju;
Romaguera, Jorge E.;
Feng, Lei;
Desai, Aakash P.;
Zhang, Liang;
Fanale, Michelle;
Samaniego, Felipe;
Hagemeister, Fredrick B.;
Fayad, Luis E.;
Rodriguez, Maria A.;
Medeiros, Jeffrey L.;
Hartig, Kimberly;
Nomie, Krystle;
Ahmed, Makhdum;
Badillo, Maria;
Ye, Haige;
Oki, Yasuhiro;
Lin, Pei;
Nastoupil, Loretta;
Westin, Jason

Publication type:

Article

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

Published in:

Oncologist, 2016, v. 21, n. 11, p. 1355, doi. 10.1634/theoncologist.2016-0104

By:

Usmani, Saad;
Ahmadi, Tahamtan;
Ng, Yvette;
Lam, Annette;
Desai, Avinash;
Potluri, Ravi;
Mehra, Maneesha

Publication type:

Article

Effects of beta-1,3-D glucan on systemic bortezomib treated rat pancreas.

Published in:

Journal of Experimental & Clinical Medicine / Deneysel ve Klinik Tip Dergisi, 2022, v. 39, n. 3, p. 743, doi. 10.52142/omujecm.39.3.29

By:

ERKAYA, Nurhan;
PARLAK, Seçil Nazife

Publication type:

Article

High-content microscopy reveals a morphological signature of bortezomib resistance.

Published in:

eLife, 2023, p. 1, doi. 10.7554/eLife.91362

By:

Kelley, Megan E.;
Berman, Adi Y.;
Stirling, David R.;
Cimini, Beth A.;
Yu Han;
Singh, Shantanu;
Carpenter, Anne E.;
Kapoor, Tarun M.;
Way, Gregory P.

Publication type:

Article

Simultaneous Inhibition Of Proteasome And Autophagy Synergistically Enhance Cytotoxicity Of Doxorubicin In Breast Cancer Cells.

Published in:

2022

By:

Jian Sheng Loh;
Nusaibah Abdul Rahim;
Yin Sim Tor;
Jhi Biau Foo

Publication type:

Abstract

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi.

Published in:

Toxicology Research, 2016, v. 5, n. 6, p. 1619, doi. 10.1039/c6tx00220j

By:

Csizmadia, Vilmos;
Hales, Paul;
Tsu, Christopher;
Ma, Jingya;
Chen, Jiejin;
Shah, Pooja;
Fleming, Paul;
Senn, Joseph J.;
Kadambi, Vivek J.;
Dick, Larry;
Wolenski, Francis S.

Publication type:

Article

High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network.

Published in:

Transplant Infectious Disease, 2014, v. 16, n. 1, p. 158, doi. 10.1111/tid.12162

By:

Marchesi, F.;
Mengarelli, A.;
Giannotti, F.;
Tendas, A.;
Anaclerico, B.;
Porrini, R.;
Picardi, A.;
Cerchiara, E.;
Dentamaro, T.;
Chierichini, A.;
Romeo, A.;
Cudillo, L.;
Montefusco, E.;
Tirindelli, M.C.;
Fabritiis, P.;
Annino, L.;
Petti, M.C.;
Monarca, B.;
Arcese, W.;
Avvisati, G.

Publication type:

Article

(-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway.

Published in:

Advances in Clinical & Experimental Medicine, 2022, v. 31, n. 7, p. 789, doi. 10.17219/acem/147268

By:

Xi Qiu;
Xiao Wu;
Weilan He

Publication type:

Article

Safety assessment of proteasome inhibitors real world adverse event analysis from the FAERS database.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-96427-3

By:

Huang, Jinlong;
Zhang, Miaomiao;
Lin, Jingyang;
Yang, Xiuli;
Huang, Ping;
Zheng, Xiaochun

Publication type:

Article

Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice.

Published in:

Scientific Reports, 2014, p. 1, doi. 10.1038/srep06370

By:

Boehmerle, Wolfgang;
Huehnchen, Petra;
Peruzzaro, Sarah;
Balkaya, Mustafa;
Endres, Matthias

Publication type:

Article

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Published in:

Scientific Reports, 2014, p. 1, doi. 10.1038/srep05240

By:

Ningning Liu;
Chunjiao Liu;
Xiaofen Li;
Siyan Liao;
Wenbin Song;
Changshan Yang;
Chong Zhao;
Hongbiao Huang;
Lixia Guan;
Peiquan Zhang;
Shouting Liu;
Xianliang Hua;
Xin Chen;
Ping Zhou;
Xiaoying Lan;
Songgang Yi;
Shunqing Wang;
Xuejun Wang;
Ping Dou, Q.;
Jinbao Liu

Publication type:

Article

Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug Development.

Published in:

Clinical Pharmacology in Drug Development, 2020, v. 9, n. 1, p. 6, doi. 10.1002/cpdd.744

By:

Tanese, Keiji;
Yamori, Takao

Publication type:

Article

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1465814

By:

Bergantim, Rui;
Peixoto da Silva, Sara;
Pinto, Vanessa;
Pereira, Joana M.;
Sousa, Diana;
Trigo, Fernanda;
Matthiesen, Rune;
Guimarães, José E.;
Vasconcelos, M. Helena

Publication type:

Article

MicroRNA-665 and its potential role in drug response and survival outcomes in multiple myeloma: a preliminary study.

Published in:

Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1465814

By:

Bergantim, Rui;
Peixoto da Silva, Sara;
Pinto, Vanessa;
Pereira, Joana M.;
Sousa, Diana;
Trigo, Fernanda;
Matthiesen, Rune;
Guimarães, José E.;
Vasconcelos, M. Helena

Publication type:

Article

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.

Published in:

Frontiers in Pharmacology, 2018, p. 1, doi. 10.3389/fphar.2018.00365

By:

Shanmugam, Muthu K.;
Ahn, Kwang S.;
Lee, Jong H.;
Kannaiyan, Radhamani;
Mustafa, Nurulhuda;
Manu, Kanjoormana A.;
Siveen, Kodappully S.;
Sethi, Gautam;
Chng, Wee J.;
Kumar, Alan P.

Publication type:

Article

MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells.

Published in:

Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00249

By:

Huang, Fang-I;
Wu, Yi-Wen;
Sung, Ting-Yi;
Liou, Jing-Ping;
Lin, Mei-Hsiang;
Pan, Shiow-Lin;
Yang, Chia-Ron

Publication type:

Article

ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma.

Published in:

Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00044

By:

Zmorzynski, Szymon;
Szudy-Szczyrek, Aneta;
Popek-Marciniec, Sylwia;
Korszen-Pilecka, Iwona;
Wojcierowska-Litwin, Magdalena;
Luterek, Małgorzata;
Chocholska, Sylwia;
Styk, Wojciech;
Swiderska-Kołacz, Grazyna;
Januszewska, Joanna;
Mielnik, Michal;
Hus, Marek;
Filip, Agata A.

Publication type:

Article

Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.

Published in:

Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1275329

By:

Binder, Adam F.;
Walker, Christopher J.;
Mark, Tomer M.;
Baljevic, Muhamed

Publication type:

Article

Metabolic signature and proteasome activity controls synovial migration of CDC42<sup>hi</sup>CD14<sup>+</sup> cells in rheumatoid arthritis.

Published in:

Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1187093

By:

Malmhäll-Bah, Eric;
Andersson, Karin M. E.;
Erlandsson, Malin C.;
Silfverswärd, Sofia T.;
Pullerits, Rille;
Bokarewa, Maria I.

Publication type:

Article

Real-world Outcomes in Newly Diagnosed Multiple Myeloma Based on Interphase Fluorescent In situ Hybridization: A Retrospective Analysis.

Published in:

Apollo Medicine, 2024, v. 21, n. 3, p. 201, doi. 10.1177/09760016241239849

By:

Jain, Punit;
Jain, Poonam;
Tikoo, Agnivesh;
Singh, Tejinder;
Patkar, Salil;
Lokhande, Vaishali;
Mishra, Anand;
Agarwal, Bharat;
Haridas, Ashwathy;
Khandelwal, Kanika

Publication type:

Article